Velsera

What Velsera does

Velsera is a global precision medicine technology company founded in 2023 by Summa Equity through the merger of Seven Bridges, PierianDx, and UgenTec. The company provides integrated AI-enhanced software and services that accelerate the discovery, development, and delivery of precision medicine, operating from its Boston headquarters with presence in the US, Europe, and Asia. Its core technology stack includes the Seven Bridges Platform (a Trusted Research Environment for bioinformatic analysis), the Clinical Genomics Workspace/CGW Plus (flagship tertiary analysis and reporting platform for NGS testing), an IVD-grade Knowledgebase powering variant interpretation (including Illumina's FDA-approved TruSight Oncology Comprehensive test), GRAF (an award-winning graph-based pangenome reference tool), ARIA (data harmonization and secure sharing), and RHEO (workflow automation for bioinformatics). The Global Data Network, launched in 2025, provides federated access to 175+ million patient records across 50+ global data providers for pharma and biotech R&D.

Velsera serves four primary customer segments: biotech and pharma (supporting 7 of the top 10 global pharmaceutical companies), clinical diagnostic laboratories (80+ active NGS lab customers processing 250,000+ samples annually), NGS assay and equipment manufacturers, and non-profits/government agencies. The company addresses concrete pain points including variant interpretation bottlenecks, FDA LDT compliance, multi-modal data silos, and slow discovery-to-diagnostic timelines. Its professional services arm deploys 150+ scientists, bioinformaticians, and engineers to support regulatory navigation, bioinformatics workflow design, and clinical lab scaling.

The business model combines SaaS platform subscriptions (Seven Bridges Platform, CGW, Knowledgebase, GRAF, ARIA) with project-based professional services, distributed through a sales-led enterprise GTM motion with quote-based annual agreements. Channel partnerships (Diagnostica Longwood for Iberia, Genoks for Turkey) extend reach into regional markets. Revenue is not publicly disclosed, but operational scale metrics — 18,000+ researchers on Seven Bridges, 250,000+ annual NGS samples, 50+ data partners, and +20% YoY sequencing volume growth — indicate a substantial enterprise footprint. Recent strategic moves include the launch of the Global Data Network, OEM partnership with Illumina on TSO Comprehensive, and senior leadership appointments in 2026 (Jamie Coffin as CEO, Kareem Saad as President and CBO) suggesting a commercial scaling phase.

Name

Velsera

Legal name

Velsera Inc.

Website

https://velsera.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

251–500 employees

Short description

Velsera is a global precision medicine technology company that provides AI-enhanced software platforms — including the Seven Bridges Platform, Clinical Genomics Workspace, and an IVD-grade Knowledgebase — and professional services to biotech and pharma companies, clinical diagnostic laboratories, NGS assay manufacturers, and non-profit research organizations.

Ownership category

akta.pro rank

Product category

Clinical Genomics Software & Bioinformatics Platforms

NAICS

Software Publishers (513210), Custom Computer Programming Services (541511), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371), Services-Health Services (8000)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Record Locator Services (RLS) & Longitudinal Record Aggregation (HLACABAH)

Keywords

• Clinical genomics software
• Bioinformatics analysis platform
• Precision medicine technology
• Multi-omic data integration
• NGS clinical reporting

Headquarters

HQ city

Charlestown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software Platform Subscriptions: SaaS-based software platform licensing for the Seven Bridges Platform, Clinical Genomics Workspace, and related analytics tools. Platforms support research, translational research, and clinical genomics workflows with enterprise agreements, data processing addendums, and statements of work governing protected health information processing.
2. Professional Services: In-house expert services including data harmonization, bioinformatics, scientific support, regulatory compliance (FDA LDT guidance, IVD verification), and clinical services supporting labs to start and scale NGS testing. Services include over 150 scientists, bioinformaticians, and engineers.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

Velsera is a global precision medicine technology company that sells integrated AI-enhanced software platforms and professional services for clinical genomics, multi-omic data analysis, and bioinformatics. Its core offerings include the Seven Bridges Trusted Research Environment, Clinical Genomics Workspace (CGW), Knowledgebase for variant interpretation, GRAF reference genome tool, ARIA data harmonization platform, RHEO workflow automation, and the Global Data Network providing federated access to 175M+ patient records. These are sold primarily through enterprise SaaS subscriptions and professional services engagements to biotech/pharma, clinical diagnostic labs, and public-sector genomics programs.

Product overview

Velsera is a global precision medicine technology company offering an integrated platform-plus-modules architecture combining AI-enhanced software and services. The core technology suite includes the Seven Bridges Platform (Trusted Research Environment for bioinformatic analysis), Clinical Genomics Workspace/CGW Plus (flagship tertiary analysis and reporting for NGS testing), Knowledgebase (IVD-grade variant interpretation knowledge base), GRAF (graph-based reference genome tool), and ARIA (data harmonization and secure sharing). RHEO provides workflow automation embedded in the Seven Bridges Platform. The Global Data Network provides federated access to 175+ million patient records. Solutions span clinical & multi-omic data access, analysis & bioinformatics, companion diagnostic development, NGS assay development, IVD compliance transition, and clinical interpretation & reporting. The company operates across the US, Europe, and Asia, serving biotech/pharma, clinical diagnostic labs, NGS assay manufacturers, and non-profits/government agencies.

Differentiator

Problem solved

Functional benefit

Brands

• Seven Bridges Platform: Trusted Research Environment (TRE) for bioinformatic analysis and pipeline development. Includes RHEO automation capabilities.
• GRAF
• ARIA
• Clinical Genomics Workspace (CGW)
• Knowledgebase
• Global Data Network (GDN)
• FastFinder

Products and services

• Seven Bridges Platform Trusted Research Environment (TRE) for bioinformatic analysis and pipeline development, enabling researchers to execute complex genomic analyses and access petabytes of public and private data; supports 18,000+ researchers.
• Clinical Genomics Workspace (CGW) Flagship tertiary analysis and reporting platform delivering confident decision support for NGS testing in clinical diagnostics, providing variant quality assessment and adaptive learning.
• CGW Plus Enhanced version of CGW featuring variant quality assessment, clinical evidence review, and adaptive learning and memory capabilities for oncology biomarker interpretation.
• Knowledgebase Best-in-class, IVD-grade variant interpretation knowledge base powering clinical decision support, including the knowledge behind Illumina's TruSight Oncology Comprehensive Test.
• GRAF (Genome Reference Annotation Flow) Award-winning reference genome tool using graph-based approaches to capture full value of diverse genomes, including African and Native American ancestries.
• ARIA Data harmonization and secure sharing platform enabling integration and sharing of multi-modal data across organizations.
• RHEO Automation framework built into the Seven Bridges Platform for executing complex, high-volume bioinformatics analyses without advanced computational skills.
• Global Data Network (GDN) Federated data ecosystem spanning 175+ million patient records across 50+ global data providers, bridging EMR, genomics, proteomics, transcriptomics, pathology, and radiology for pharma R&D.
• Professional Services: Data Harmonization In-house expert services supporting health and life science companies to combine and harmonize their data, delivered by 150+ scientists, bioinformaticians, and engineers.
• Professional Services: Bioinformatics In-house expert bioinformatics services supporting researchers and diagnostic developers to build better workflows.
• Professional Services: Regulatory

Quantifiable outcome

• 7/10 top pharmaceutical companies supported by Velsera technology-enabled products and services
• +8 more outcomes

Named customers19 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• IlluminacoreOEM/ Whitelabel/ Licensing Partner · 30 May 2025Velsera powers the Knowledgebase behind Illumina's TruSight Oncology Comprehensive Test, now approved in Japan. This IVD-grade variant interpretation knowledge base supports comprehensive genomic profiling for cancer diagnostics.
• Diagnostica LongwoodcoreChannel Partner/ Reseller/ Distributor · 8 October 2024Partnership to revolutionize access to precision genomics for patients in Spain and Portugal, with Diagnostica Longwood distributing and supporting Velsera's technologies in the Iberian Peninsula.
• Genoks GDHMcoreStrategic or Co-development Partner · 28 June 2024Strategic partnership to advance cancer diagnostics in Turkey, enabling local access to precision genomics technologies and supporting the expansion of NGS testing capabilities in the region.
• SentieonminorStrategic or Co-development Partner · 3 June 2024Joint development of Pangenotyper solution using graph-based pangenome reference for enhanced variant calling, which won Bio-IT World 2024 Best-of-Show award.
• Solaris HealthcoreStrategic or Co-development Partner · 3 November 2023Partnership to expand access to genetic testing for urology patients to help understand cancer risks, enabling broader patient access to precision medicine diagnostics.
• Arima GenomicsminorStrategic or Co-development Partner · 7 February 2023Partnership to enable broad adoption of Arima Gene Fusion Test in clinical laboratories, integrating Arima's testing technology with Velsera's clinical genomics workflow platform.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• DNAnexus: DNAnexus provides a cloud-based biomedical informatics and data management platform for genomic and clinical data. Like Velsera's Seven Bridges Trusted Research Environment, it hosts large-scale NGS pipelines for pharma and clinical labs, making it the closest direct competitor on the research informatics side.
• Congenica: Congenica provides a clinical genomics interpretation platform used in rare disease and oncology diagnostics. It overlaps directly with Velsera's Clinical Genomics Workspace and Knowledgebase in clinical NGS interpretation workflows for hospital and reference labs.
• BC Platforms: BC Platforms operates a genomic data platform with a BCRQUEST.com data network of real-world clinical and genomic records, comparable to Velsera's Global Data Network. It serves pharma R&D and clinical diagnostics with a similar data-access and analytics model.
• SOPHiA Genetics: SOPHiA Genetics offers an AI-driven platform for genomic analysis and interpretation used by clinical labs and hospitals worldwide. It competes head-to-head with Velsera's CGW/CGW Plus for tertiary NGS analysis and variant interpretation, particularly in oncology and rare disease applications.
• Fabric Genomics (Genomic Health / Exact Sciences): Fabric Genomics (acquired by Genomic Health / Exact Sciences) provides AI-based NGS interpretation software for hereditary and oncology testing. Its interpretation capabilities compete with CGW in clinical labs scaling NGS testing for germline and somatic variants.

Broad incumbents

• Illumina (DRAGEN / Connected Software): Illumina is the dominant sequencing platform vendor and now offers DRAGEN secondary analysis and Connected Software tertiary pipelines. It is both a partner (via the TSO Comprehensive / Knowledgebase relationship) and a competitive threat vertically integrating into clinical interpretation workflows where CGW operates.
• Flatiron Health: Flatiron Health (a Roche subsidiary) operates a real-world oncology data platform that aggregates de-identified clinical and molecular data from cancer clinics. It is a broad incumbent comparable to Velsera's Global Data Network in pharma R&D data access for oncology.
• Roche (navify / Foundation Medicine): Roche operates the navify digital diagnostics platform and Foundation Medicine for companion diagnostics and oncology data. As a leading IVD and pharma company vertically integrating into clinical genomics informatics, it represents a broad incumbent comparable to Velsera's companion diagnostic and clinical interpretation stack.

Emerging players

• Lifebit: Lifebit provides federated genomics and biomedical data platforms (e.g., Lifebit CloudOS) for national genomics initiatives and pharma. It is an emerging peer with partial overlap to Seven Bridges on Trusted Research Environments and federated genomic data analysis.
• Seqera Labs: Seqera (the commercial entity behind Nextflow) provides cloud-native scientific workflow orchestration for bioinformatics pipelines. It competes with portions of Velsera's Seven Bridges / RHEO pipeline automation stack in life sciences research workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/velseraofficial
• LinkedInlinkedin.com/company/velseraofficial

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Velsera